---
title: Inhibiting H3K27 Demethylases Downregulates CREB-CREBBP, Overcoming Resistance
  in Relapsed Acute Lymphoblastic Leukemia
date: '2025-01-10'
linkTitle: https://pubmed.ncbi.nlm.nih.gov/39791538/?utm_source=curl&utm_medium=rss&utm_campaign=pubmed-2&utm_content=1FakS-2QOkCT8HsMOQP1bCRQ4YzyumYOmxmF0moLsQ3dFB1E9V&fc=20220326224207&ff=20250110170846&v=2.18.0.post9+e462414
source: heidelberg[Affiliation]
description: 'CONCLUSIONS: This study proposes H3K27 demethylase inhibition as a potential
  treatment strategy for patients with treatment-resistant ALL, using CREBBP as a
  biomarker for drug response and combining GSK-J4 with venetoclax and navitoclax
  as synergistic ...'
disable_comments: true
---
CONCLUSIONS: This study proposes H3K27 demethylase inhibition as a potential treatment strategy for patients with treatment-resistant ALL, using CREBBP as a biomarker for drug response and combining GSK-J4 with venetoclax and navitoclax as synergistic ...